EUCTR2018-001393-16-FR进行中（未招募）1 期
A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compared to Standard Neonatal Care in Extremely Premature Infants
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Premacure AB
- 入组人数
- 477
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consents and/or assents must be signed and dated by the subject's parent(s) prior to any study-related procedures. The informed consent and any assents for underage parents must be approved by the institutional review board (IRB)/independent ethics committee (IEC).
- •2. Written informed consents and/or assents must be signed and dated by the subject's birth mother prior to providing study-related information related to birth mother medical history, pregnancy and the birth of the subject. The informed consent and any assents for underage birth mothers must be approved by the IRB/IEC.
- •3. Initially, subjects must be between GA of 26 weeks +0 days and 27 weeks +6 days, inclusive. After approximately 75 subjects (approximately 25 subjects in each treatment group) have completed the PMA 40 weeks visit, an independent DMC will assess safety data and may authorize enrollment of subjects of GA between 23 weeks +0 days and 27 weeks +6 days, inclusive.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 477
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Detectable major (or severe) congenital malformation identified before randomization.
- •2. Known or suspected chromosomal abnormality, genetic disorder, or syndrome, identified before randomization, according to the investigator’s opinion.
- •3. Hypoglycemia at Baseline (blood glucose <45 mg/dL or 2.5 mmol/L) which persists in spite of glucose supplementation, to exclude severe congenital abnormalities of glucose metabolism.
- •4. Clinically significant neurological disease identified before randomization according to cranial ultrasound (hemorrhages confined to the germinal matrix are allowed) and
- •investigator’s opinion.
- •5. Any other condition or therapy that, in the investigator’s opinion, may pose a risk to the subject or interfere with the subject’s potential compliance with this protocol or interfere with interpretation of results.
- •6. Current or planned participation in a clinical study of another investigational study drug, device, or procedure (participation in observational studies is permitted on a case-by-case basis).
- •7. The subject or subject’s parent(s) is/are unable to comply with the protocol or is unlikely to be available for long-term follow-up as determined by the investigator.
- •Major (or severe) congenital malformations include structurally significant congenital heart disease, and structural abnormalities of the upper airway, lungs or chest wall. Congenital malformations that are suspected of being associated with chromosomal abnormalities, genetic syndromes, and neoplasia should be excluded, as well as abnormalities that may affect life expectancy, cardio-pulmonary development, neurologic development, or
- •interpretation of study results.
- •Isolated minor dysmorphic anomalies that are unlikely to be exclusionary could include post-axial polydactyly, ankyloglossia, accessory nipples, preauricular pits, single or horizontal palmar crease, clinodactyly, and single umbilical artery. However, the presence of multiple minor anomalies in the same infant may be exclusionary.
- •Uncomplicated infantile hemangiomas are unlikely to be exclusionary. However, infantile hemangiomas that may be associated with potential for disfigurement, life-threatening complications, functional impairment, ulceration, or underlying abnormalities should be excluded.
- •Inclusion/exclusion will ultimately be determined by the investigator, based on assessment of the clinical presentation of each candidate subject and the likelihood that physical finding(s) are associated with a condition that impacts health and development.
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the safety and efficacy of an experimental drug for chronic lung disease against normally prescribed care in extremely premature babiesChronic Lung DiseaseMedDRA version: 20.0Level: LLTClassification code 10066204Term: Chronic lung disease of prematuritySystem Organ Class: 100000004855EUCTR2018-001393-16-PLPremacure AB, A Member of the Shire Group of Companies600
进行中（未招募）
2 期
A Clinical Efficacy and Safety Study of SHP607 in Preventing Chronic Lung Disease in Extremely Premature InfantsChronic Lung DiseaseJPRN-jRCT2071200076ishizawa Atsushi81
招募中
2 期
A study evaluating the safety and efficacy of an experimental drug for chronic lung disease against normally prescribed care in extremely premature babies2024-515914-41-00Ohb Neonatology Limited60
进行中（未招募）
1 期
A study evaluating the safety and efficacy of an experimental drug for chronic lung disease against normally prescribed care in extremely premature babiesChronic Lung DiseaseMedDRA version: 21.1Level: LLTClassification code 10066204Term: Chronic lung disease of prematuritySystem Organ Class: 100000004855EUCTR2018-001393-16-IEOak Hill Bio477
进行中（未招募）
1 期
A study evaluating the safety and efficacy of an experimental drug forchronic lung disease against normally prescribed care in extremelypremature babiesEUCTR2018-001393-16-ITPREMACURE AB, A MEMBER OF SHIRE GROUP OF COMPANIES600